UK markets closed

Moleculin Biotech, Inc. (MBRX)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
4.9300-0.0800 (-1.60%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 11.40M
Enterprise value -4.87M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.53
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.52

Trading information

Stock price history

Beta (5Y monthly) 1.85
52-week change 3690.06%
S&P500 52-week change 326.14%
52-week high 36.2400
52-week low 30.3380
50-day moving average 34.4979
200-day moving average 31.5397

Share statistics

Avg vol (3-month) 392.92k
Avg vol (10-day) 315.43k
Shares outstanding 52.31M
Implied shares outstanding 62.41M
Float 81.93M
% held by insiders 14.65%
% held by institutions 115.53%
Shares short (30 Apr 2024) 431.1k
Short ratio (30 Apr 2024) 41.22
Short % of float (30 Apr 2024) 41.39%
Short % of shares outstanding (30 Apr 2024) 41.35%
Shares short (prior month 28 Mar 2024) 444.95k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 301 Feb 2021
Ex-dividend date 4N/A
Last split factor 21:15
Last split date 322 Mar 2024

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-38.73%
Return on equity (ttm)-76.07%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -29.5M
Net income avi to common (ttm)-29.77M
Diluted EPS (ttm)-15.1500
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)23.55M
Total cash per share (mrq)10.57
Total debt (mrq)574k
Total debt/equity (mrq)2.20%
Current ratio (mrq)3.86
Book value per share (mrq)11.70

Cash flow statement

Operating cash flow (ttm)-24.1M
Levered free cash flow (ttm)-14.6M